DDAVP TABLETS 0.1MG 0.1 MG
DESMOPRESSIN ACETATE : 0.1 MG · DIN 00824305 · FERRING INC
Health Canada status: CANCELLED POST MARKET
What is DDAVP TABLETS 0.1MG?
DDAVP TABLETS 0.1MG 0.1 MG contains DESMOPRESSIN ACETATE : 0.1 MG. It is listed in the Health Canada Drug Product Database under DIN 00824305, held by FERRING INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-May-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DDAVP TABLETS 0.1MG used for?
Treatment of Central Diabetes Insipidus; control of temporary polyuria/polydipsia following head trauma or surgery; management of Primary Nocturnal Enuresis in patients 5 years and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00824305 |
|---|---|
| Brand name | DDAVP TABLETS 0.1MG |
| Generic / active ingredient | DESMOPRESSIN ACETATE : 0.1 MG |
| Manufacturer | FERRING INC |
| Strength | 0.1 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | H01BA02 DESMOPRESSIN |
| AHFS class | 68:28.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-May-2022 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Diabetes Insipidus: Start 0.1 mg tid, max 1.2 mg/day. Nocturnal Enuresis: Start 0.2 mg 1 hour before bedtime, max 0.6 mg. Fluid restriction is essential.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C - 25°C in a dry place.
How is it supplied?
Bottles of 30 or 100 tablets.
Contraindications
Hypersensitivity; Type IIB or platelet-type von Willebrand disease; hyponatremia; severe liver disease; nephrosis; cardiac/renal insufficiency; congestive heart failure; polydipsia; sodium-losing states.
Warnings and precautions
Risk of water intoxication and hyponatremia; fluid intake must be restricted. Use caution in patients with coronary artery insufficiency or cystic fibrosis. Contains lactose.
Is DESMOPRESSIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by AA PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code H01BA02 DESMOPRESSIN. 10 of 29 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DESMOPRESSIN | 0.1 MG | TABLET | APOTEX INC | MARKETED | DIN 02284030 |
| APO-DESMOPRESSIN | 0.2 MG | TABLET | APOTEX INC | MARKETED | DIN 02284049 |
| BIPAZEN | 4 MCG | SOLUTION | KVR PHARMACEUTICALS INC. | MARKETED | DIN 02513579 |
| DDAVP INJ 4MCG/ML | 4 MCG | LIQUID | FERRING INC | MARKETED | DIN 00873993 |
| DDAVP MELT | 120 MCG | TABLET (ORALLY DISINTEGRATING) | FERRING INC | MARKETED | DIN 02285002 |
| DDAVP MELT | 60 MCG | TABLET (ORALLY DISINTEGRATING) | FERRING INC | MARKETED | DIN 02284995 |
| DESMOPRESSIN SPRAY | 10 MCG | SPRAY, METERED DOSE | AA PHARMA INC | MARKETED | DIN 02242465 |
| OCTOSTIM LIQ INJ. 15MCG/ML | 15 MCG | SOLUTION | FERRING INC | MARKETED | DIN 02024179 |
| PMS-DESMOPRESSIN | 0.1 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02304368 |
| PMS-DESMOPRESSIN | 0.2 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02304376 |
Who else supplies DESMOPRESSIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DESMOPRESSIN appears in 136 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.